PORTOLA PHARMACEUTICALS INC's ticker is PTLA and the CUSIP is 737010108. A total of 151 filers reported holding PORTOLA PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 0.54 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $2,187,000 | -89.4% | 306,764 | -64.5% | 0.01% | -86.5% |
| Q4 2019 | $20,643,000 | +203.5% | 864,456 | +240.9% | 0.04% | +428.6% |
| Q3 2019 | $6,802,000 | +100.8% | 253,600 | +159.7% | 0.01% | 0.0% |
| Q1 2019 | $3,388,000 | +160.8% | 97,642 | +46.7% | 0.01% | +133.3% |
| Q4 2018 | $1,299,000 | -81.5% | 66,542 | -74.8% | 0.00% | -80.0% |
| Q3 2018 | $7,019,000 | -68.1% | 263,572 | -54.7% | 0.02% | -71.7% |
| Q2 2018 | $21,998,000 | +12.5% | 582,426 | -2.7% | 0.05% | +10.4% |
| Q1 2018 | $19,548,000 | -43.5% | 598,531 | -15.8% | 0.05% | -46.1% |
| Q4 2017 | $34,599,000 | +33.8% | 710,734 | +48.5% | 0.09% | +21.9% |
| Q3 2017 | $25,864,000 | +34.4% | 478,690 | -8.3% | 0.07% | +23.7% |
| Q2 2017 | $19,244,000 | -22.2% | 522,237 | -17.2% | 0.06% | -27.2% |
| Q1 2017 | $24,723,000 | +63.3% | 630,858 | -6.5% | 0.08% | +44.6% |
| Q4 2016 | $15,141,000 | +13.7% | 674,752 | +15.1% | 0.06% | +12.0% |
| Q3 2016 | $13,312,000 | -29.1% | 586,155 | -14.3% | 0.05% | -31.5% |
| Q2 2016 | $18,787,000 | +771.8% | 683,641 | +793.6% | 0.07% | +630.0% |
| Q1 2016 | $2,155,000 | +188.9% | 76,500 | +427.6% | 0.01% | +233.3% |
| Q4 2015 | $746,000 | -84.3% | 14,500 | -87.0% | 0.00% | -85.7% |
| Q3 2015 | $4,737,000 | -33.3% | 111,150 | -22.7% | 0.02% | -27.6% |
| Q2 2015 | $7,107,000 | +98.6% | 143,750 | +43.4% | 0.03% | +93.3% |
| Q1 2015 | $3,578,000 | -22.5% | 100,250 | -38.5% | 0.02% | -28.6% |
| Q4 2014 | $4,617,000 | +108.2% | 163,022 | +85.8% | 0.02% | +90.9% |
| Q3 2014 | $2,218,000 | -10.4% | 87,750 | +3.4% | 0.01% | -8.3% |
| Q2 2014 | $2,476,000 | +52.4% | 84,850 | +35.2% | 0.01% | +50.0% |
| Q1 2014 | $1,625,000 | +21.3% | 62,750 | +20.6% | 0.01% | +14.3% |
| Q4 2013 | $1,340,000 | +7.1% | 52,050 | +11.3% | 0.01% | 0.0% |
| Q3 2013 | $1,251,000 | +51.1% | 46,750 | +38.7% | 0.01% | +40.0% |
| Q2 2013 | $828,000 | – | 33,700 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fernwood Investment Management, LLC | 228,873 | $7,475,000 | 4.17% |
| PFM Health Sciences, LP | 5,326,671 | $173,969,000 | 3.54% |
| Marcus Capital, LLC | 22,950 | $750,000 | 2.76% |
| Partner Investment Management, L.P. | 72,284 | $2,361,000 | 2.55% |
| CADIAN CAPITAL MANAGEMENT, LP | 1,240,944 | $40,529,000 | 2.19% |
| HARVEY CAPITAL MANAGEMENT INC | 158,580 | $5,179,000 | 1.94% |
| SECTORAL ASSET MANAGEMENT INC | 498,412 | $16,278,000 | 1.78% |
| Everett Capital Advisors UK LLP | 551,173 | $18,001,000 | 1.52% |
| ROSENBLUM SILVERMAN SUTTON S F INC /CA | 125,210 | $4,089,000 | 1.46% |
| Atika Capital Management LLC | 113,000 | $3,691,000 | 1.26% |